Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis

Summary

Atherosclerosis is at least in part an inflammatory disease. CD14 is an endotoxin receptor that after binding of lipopolysaccharides evokes endothelial activation and secretion of several cytokines. A polymorphism of CD14 has been associated with myocardial infarction. We evaluated the role of the -159 T/C polymorphism in the promoter region of the CD14 gene in relation to severity and progression of coronary atherosclerosis and response to the HMG CoA reductase inhibitor pravastatin. We recruited patients from the multicenter double-blind randomized placebo controlled REGRESS trial and genotyped the -159T/C CD14 polymorphism. DNA and angiographic follow-up were available from 759 patients with objectivated coronary artery disease. We measured changes in mean segment diameter (MSD) and minimum obstruction diameter (MOD) with quantitative coronary angiography and noted the occurrence of major adverse cardiac events. The genotype distribution was 28% TT, 49% CT, 23% CC. We did not find any association between genotype and MSD and MOD at baseline, frequency of previous myocardial infarction, changes in MSD and MOD or major clinical events. Treatment with the HMG CoA reductase inhibitor pravastatin reduced progression of coronary atherosclerosis and adverse events equally for all genotypes. We conclude, that the -159T/C polymorphism in the CD14 monocyte receptor gene was not associated with progression of coronary atherosclerosis in this population nor did it influence the efficacy of pravastatin in the treatment of atherosclerosis.

Keywords

Atherosclerosis - clinical/epidemiological studies - gene mutations - inflammatory mediators - ischaemic heart disease

• References

• 1 Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340 (02) 115-26.
• 2 Espinola-Klein C, Rupprecht HJ, Blankenberg S. et al. Impact of Infectious Burden on Extent and Long-Term Prognosis of Atherosclerosis. Circulation 2002; 105 (01) 15-21.
• 3 Liao W. Endotoxin: possible roles in initiation and development of atherosclerosis. J Lab Clin Med 1996; 128 (05) 452-60.
• 4 Pugin J, Heumann ID, Tomasz A. et al. CD14 Is a Pattern Recognition Receptor. Immunity 1994; 01: 509-16.
• 5 Devitt A, Moffatt OD, Raykundalia C. et al. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998; 392 (6675): 505-9.
• 6 Frey EA, Miller DS, Jahr TG. et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992; 176 (06) 1665-71.
• 7 Crisby M, Kallin B, Thyberg J. et al. Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis 1997; 130 (1-2): 17-27.
• 8 Goyert SM, Ferrero E, Rettig WJ. et al. The CD14 monocyte differentiation antigen maps to a region encoding growth factors and receptors. Science 1988; 239 (4839): 497-500.
• 9 Zhang DE, Hetherington CJ, Tan S. et al. Sp1 is a critical factor for the monocytic specific expression of human CD14. J Biol Chem 1994; 269 (15) 11425-34.
• 10 Hubacek JA, Stuber F, Frohlich D. et al. The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun 2000; 01 (06) 405-7.
• 11 Baldini M, Carla ILohman, Halonen M. et al. A Polymorphism* in the 5’ Flanking Region of the CD14 Gene Is Associated with Circulating Soluble CD14 Levels and with Total Serum Immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20 (05) 976-83.
• 12 Unkelbach K, Gardemann A, Kostrzewa M. et al. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999; 19 (04) 932-8.
• 13 Kondo T, Ohno M, Shimokata K. et al. CD14 promoter polymorphism is associated with acute myocardial infarction resulting from insignificant coronary artery stenosis. Heart 2003; 89 (08) 931-2.
• 14 Shimada K, Watanabe Y, Mokuno H. et al. Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. Am J Cardiol 2000; 86 (06) 682-4.
• 15 Zee RYL, Lindpaintner K, Struk B. et al. A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. Atherosclerosis 2001; 154 (03) 699-702.
• 16 Jukema JW, Bruschke AV, van Boven AJ. et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91 (10) 2528-40.
• 17 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16 (03) 1215.
• 18 Elghannam H, Tavackoli S, Ferlic L. et al. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med 2000; 78 (10) 562-8.
• 19 Koch W, Kastrati A, Mehilli J. et al. CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction. Am Heart J 2002; 143 (06) 971-6.
• 20 Koenig W, Khuseyinova N, Hoffmann MM. et al. CD14 C(-260)->T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. J Am Coll Cardiol 2002; 40 (01) 34-42.
• 21 Nauck M, Winkelmann BR, Hoffmann MM. et al. C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Am J Cardiol 2002; 90 (11) 1249-52.
• 22 Agema WRP, Jukema JW, Zwinderman AH. et al. A meta-analysis of the ACE gene polymorphism and restenosis after percutaneous transluminal coronary revascularisation. Evidence for publication bias. Am Heart J 2002; 144: 760-8.
• 23 Eng HL, Chen CH, Kuo CC. et al. Association of CD14 promoter gene polymorphism and Chlamydia pneumoniae infection. J Infect Dis 2003; 188 (01) 90-7.
• 24 Wong YK, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. Heart 1999; 81 (03) 232-8.
• 25 Laflamme N, Rivest S. Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gramnegative bacterial cell wall components. FASEB J 2001; 15 (01) 155-63.
• 26 Boekholdt SM, Agema WRP, Peters RJG. et al. Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events. Circulation 2003; 107 (19) 2416.